HUNTERSVILLE,Orthofix has received FDA approval for a new product called Cervical-Stim, a bone-growth stimulator that can be used in patients receiving spine fusion treatments.

Orthofix offers a variety of non-invasive products for spine and long-bone fractures.

“We expect this milestone to establish us as the market growth leader in the spine stimulation business in 2005,” said Charles Federico, CEO of Orthofix, in a statement.

Federico said the spine stimulation market is expected to be $205 million in 2005.

FDA approval came after a clinical investigation involving 323 patients who had received cervical fusion to combat degenerative conditions. The study was led by Ken Foley, a doctor at the University of Tennessee’s Department of Neurosurgery.